Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2012, Article ID 468609, 4 pages
http://dx.doi.org/10.1155/2012/468609
Case Report

Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration

Fort Bend Premier Care, 1505 Liberty Street, Richmond, TX 77469, USA

Received 24 December 2011; Accepted 9 January 2012

Academic Editors: K. Iida, H. Ikeda, M. P. Kane, and R. Swaminathan

Copyright © 2012 I. N. Mefford et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. V. A. Fonseca, “Defining and characterizing the progression of type 2 diabetes,” Diabetes Care, vol. 32, pp. S151–156, 2009. View at Google Scholar · View at Scopus
  3. P. Marchetti, R. Lupi, S. Del Guerra et al., “Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control,” Diabetes Care, vol. 32, pp. S178–183, 2009. View at Google Scholar · View at Scopus
  4. J. J. Meier, A. E. Butler, R. Galasso, R. A. Rizza, and P. C. Butler, “Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans,” Diabetologia, vol. 49, no. 11, pp. 2689–2696, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. I. Rooman, J. Lardon, and L. Bouwens, “Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue,” Diabetes, vol. 51, no. 3, pp. 686–690, 2002. View at Google Scholar · View at Scopus
  6. W. L. Suarez-Pinzon, Y. Yan, R. Power, S. J. Brand, and A. Rabinovitch, “Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice,” Diabetes, vol. 54, no. 9, pp. 2596–2601, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. I. N. Mefford and E. U. Wade, “Proton pump inhibitors as a treatment method for type II diabetes,” Medical Hypotheses, vol. 73, no. 1, pp. 29–32, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. I. N. Mefford, M. A. Crouch, and E. U. Wade, “Effect of concomitant proton pump inhibitor therapy on type 2 diabetes control,” Family Medicine, vol. 42, supplement 2, 2010. View at Google Scholar
  9. K. D. Hove, K. Færch, T. B. Bödvarsdóttir, A. E. Karlsen, J. S. Petersen, and A. Vaag, “Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients—a retrospective analysis,” Diabetes Research and Clinical Practice, vol. 90, no. 3, pp. e72–e74, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. Boj-Carcellar, P. Bocos-Terraz, and M. Moreno-Verniz, “Are proton pump inhibitors a new antidiabetic drug? A cross sectional study,” World Journal of Diabetes, vol. 2, no. 12, pp. 217–220, 2011. View at Google Scholar
  11. W. L. Suarez-Pinzon, G. S. Cembrowski, and A. Rabinovitch, “Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice,” Diabetologia, vol. 52, no. 8, pp. 1680–1682, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. T. B. Bödvarsdóttir, K. D. Hove, C. F. Gotfredsen et al., “Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes,” Diabetologia, vol. 53, no. 10, pp. 2220–2223, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. H. Koop, M. Klein, and R. Arnold, “Serum gastrin levels during long-term omeprazole treatment,” Alimentary Pharmacology and Therapeutics, vol. 4, no. 2, pp. 131–138, 1990. View at Google Scholar · View at Scopus
  14. D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Google Scholar · View at Scopus
  15. J. J. Meier, B. A. Menge, T. G. K. Breuer et al., “Functional assessment of pancreatic β-cell area in humans,” Diabetes, vol. 58, no. 7, pp. 1595–1603, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Tougas, D. L. Earnest, Y. Chen, C. Vanderkoy, and M. Rojavin, “Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 1, pp. 59–65, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Sanaka, T. Yamamoto, and Y. Kuyama, “Effects of proton pump inhibitors on gastric emptying: a systematic review,” Digestive Diseases and Sciences, vol. 55, no. 9, pp. 2431–2440, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. J. Brand and D. Stone, “Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria,” Journal of Clinical Investigation, vol. 82, no. 3, pp. 1059–1066, 1988. View at Google Scholar · View at Scopus
  19. A. Theodoraki, B. Khoo, A. Hamda, F. Grillo, T. Meyer, and P. M. G. Bouloux, “Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations,” Endocrine Practice, vol. 16, no. 5, pp. 835–837, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus